Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Chinese Patent Office
Federal Trade Commission
McKesson
Express Scripts
US Department of Justice
Cipla
Baxter
QuintilesIMS
Johnson and Johnson

Generated: August 19, 2017

DrugPatentWatch Database Preview

Insulin recombinant human; insulin susp isophane recombinant human - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for insulin recombinant human; insulin susp isophane recombinant human and what is the scope of insulin recombinant human; insulin susp isophane recombinant human freedom to operate?

Insulin recombinant human; insulin susp isophane recombinant human
is the generic ingredient in four branded drugs marketed by Lilly and Novo Nordisk Inc, and is included in three NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Insulin recombinant human; insulin susp isophane recombinant human has twelve patent family members in nine countries.

There are thirty-eight drug master file entries for insulin recombinant human; insulin susp isophane recombinant human. Four suppliers are listed for this compound.

Summary for Generic Name: insulin recombinant human; insulin susp isophane recombinant human

Tradenames:4
Patents:1
Applicants:2
NDAs:3
Drug Master File Entries: see list38
Suppliers / Packagers: see list4
Clinical Trials: see list11,578
Drug Prices:see low prices
DailyMed Link:insulin recombinant human; insulin susp isophane recombinant human at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
HUMULIN 70/30
insulin recombinant human; insulin susp isophane recombinant human
INJECTABLE;INJECTION019717-001Apr 25, 1989OTCYesYes► Subscribe► SubscribeY ► Subscribe
Lilly
HUMULIN 70/30 PEN
insulin recombinant human; insulin susp isophane recombinant human
INJECTABLE;INJECTION019717-002Aug 6, 1998OTCYesYes► Subscribe► SubscribeY ► Subscribe
Lilly
HUMULIN 50/50
insulin recombinant human; insulin susp isophane recombinant human
INJECTABLE;INJECTION020100-001Apr 29, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Novo Nordisk Inc
NOVOLIN 70/30
insulin recombinant human; insulin susp isophane recombinant human
INJECTABLE;INJECTION019991-001Jun 25, 1991OTCYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: insulin recombinant human; insulin susp isophane recombinant human

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,427,275Medication dispensing apparatus with triple screw threads for mechanical advantage► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: insulin recombinant human; insulin susp isophane recombinant human

Country Document Number Estimated Expiration
South Korea101121317► Subscribe
Norway20061150► Subscribe
European Patent Office1656170► Subscribe
South Korea20060061822► Subscribe
Japan2007502146► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0020France► SubscribePRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
90029-5Sweden► SubscribePRODUCT NAME: INSULIN DEGLUDEK
00160Netherlands► SubscribePRODUCT NAME: INSULINE DETEMIRUM; NAT. REGISTRATION NO/DATE: EU/1/04/278/001EU/1/04/278/002EU/1/04/278/003EU/1/04/278/005EU/1/04/278/004EU/1/04/278/006EU/1/04/278/007EU/1/04/278/008EU/1/04/278/009 2004010601; FIRST REGISTRATION: 563705637156372EU/1/04/278/001 T/M -/009 2003101110
C/GB00/027United Kingdom► SubscribePRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
90067-4Sweden► SubscribePRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Queensland Health
QuintilesIMS
Colorcon
Harvard Business School
Dow
Deloitte
AstraZeneca
Johnson and Johnson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot